Callan Capital LLC Has $839,000 Stock Holdings in Danaher Co. (NYSE:DHR)

Callan Capital LLC increased its position in shares of Danaher Co. (NYSE:DHR) by 232.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,358 shares of the conglomerate’s stock after buying an additional 2,347 shares during the quarter. Callan Capital LLC’s holdings in Danaher were worth $839,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Cape Investment Advisory Inc. bought a new position in shares of Danaher in the fourth quarter valued at approximately $25,000. Tsfg LLC increased its position in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after buying an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher in the 2nd quarter valued at $25,000. nVerses Capital LLC bought a new position in Danaher during the 2nd quarter worth about $25,000. Finally, Redmont Wealth Advisors LLC bought a new position in Danaher during the 1st quarter worth about $30,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,659 shares of company stock valued at $11,042,433. Company insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DHR. Evercore ISI reduced their price objective on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. TD Cowen raised their target price on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a research note on Friday, September 6th. Finally, Stifel Nicolaus raised their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Trading Up 1.7 %

Shares of DHR opened at $276.43 on Friday. The stock has a market capitalization of $204.75 billion, a P/E ratio of 46.85, a PEG ratio of 4.48 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a fifty day simple moving average of $267.10 and a two-hundred day simple moving average of $257.03. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the company posted $2.05 EPS. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. On average, research analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. Danaher’s dividend payout ratio is 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.